Vaccine. 2004 Dec 6;22 Suppl 1:S39-43.

A humanized monoclonal antibody targeting Staphylococcus aureus.

Source

Inhibitex Inc., 1165 Westside Parkway, Suite 400, Alpharetta, GA 30004, USA. jpatti@inhibitex.com

Abstract

This current presentation describes the in vitro and in vivo characterization of Aurexis (tefibazumab), a humanized monoclonal antibody that exhibits a high affinity and specificity and for the Staphylococcus aureus MSCRAMM (Microbial Surface Components Recognizing Adhesive Matrix Molecules) protein ClfA. Aurexis inhibited ClfA binding to human fibrinogen, and enhanced the opsonophagocytic uptake of ClfA-coated beads. Preclinical in vivo testing revealed that a single administration of Aurexis significantly protected against an IV challenge with a methicillin resistant S. aureus (MRSA) strain in murine septicemia and rabbit infective endocarditis (IE) models. Safety and pharmacokinetic data from a 19-patient phase I study support continued evaluation of Aurexis in phase II studies.

PMID:: 15576200; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Staphylococcal Infections - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. [Infect Immun. 2003]
Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A.
Hall AE, Domanski PJ, Patel PR, Vernachio JH, Syribeys PJ, Gorovits EL, Johnson MA, Ross JM, Hutchins JT, Patti JM. Infect Immun. 2003 Dec; 71(12):6864-70.
Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus. [Infect Immun. 2005]
Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus.
Domanski PJ, Patel PR, Bayer AS, Zhang L, Hall AE, Syribeys PJ, Gorovits EL, Bryant D, Vernachio JH, Hutchins JT, et al. Infect Immun. 2005 Aug; 73(8):5229-32.
Review Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection. [Curr Opin Mol Ther. 2006]
Review Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection.
John JF Jr. Curr Opin Mol Ther. 2006 Oct; 8(5):455-60.
Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. [Antimicrob Agents Chemother. 2...]
Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo.
Vernachio JH, Bayer AS, Ames B, Bryant D, Prater BD, Syribeys PJ, Gorovits EL, Patti JM. Antimicrob Agents Chemother. 2006 Feb; 50(2):511-8.
Review MSCRAMM--targeted vaccines and immunotherapy for staphylococcal infection. [Curr Opin Drug Discov Devel. 2...]
Review MSCRAMM--targeted vaccines and immunotherapy for staphylococcal infection.
Rivas JM, Speziale P, Patti JM, Höök M. Curr Opin Drug Discov Devel. 2004 Mar; 7(2):223-7.

See reviews... See all...

Cited by 6 PubMed Central articles

Functional antibodies targeting IsaA of Staphylococcus aureus augment host immune response and open new perspectives for antibacterial therapy. [Antimicrob Agents Chemother. 2...]
Functional antibodies targeting IsaA of Staphylococcus aureus augment host immune response and open new perspectives for antibacterial therapy.
Lorenz U, Lorenz B, Schmitter T, Streker K, Erck C, Wehland J, Nickel J, Zimmermann B, Ohlsen K. Antimicrob Agents Chemother. 2011 Jan; 55(1):165-73. Epub 2010 Oct 18.
Review Novel targeted immunotherapy approaches for staphylococcal infection. [Expert Opin Biol Ther. 2010]
Review Novel targeted immunotherapy approaches for staphylococcal infection.
Otto M. Expert Opin Biol Ther. 2010 Jul; 10(7):1049-59.
Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. [Nat Protoc. 2009]
Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen.
Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, Wilson PC. Nat Protoc. 2009; 4(3):372-84.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

A humanized monoclonal antibody targeting Staphylococcus aureus.
A humanized monoclonal antibody targeting Staphylococcus aureus.
Vaccine. 2004 Dec 6 ;22 Suppl 1:S39-43.

PubMed
Structural basis for the activity of drugs that inhibit phosphodiesterases.
Structural basis for the activity of drugs that inhibit phosphodiesterases.
Structure. 2004 Dec ;12(12):2233-47.

PubMed
Hidden localization motifs: naturally occurring peroxisomal targeting signals in...
Hidden localization motifs: naturally occurring peroxisomal targeting signals in non-peroxisomal proteins.
Genome Biol. 2004 ;5(12):R97. Epub 2004 Nov 30 .

PubMed
A Drosophila protein-interaction map centered on cell-cycle regulators.
A Drosophila protein-interaction map centered on cell-cycle regulators.
Genome Biol. 2004 ;5(12):R96. Epub 2004 Nov 26 .

PubMed
Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analy...
Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis.
Allergy. 2005 Jan ;60(1):4-12.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: